Vasopressin and methylprednisolone and hemodynamics after in-hospital cardiac arrest - A post hoc analysis of the VAM-IHCA trial.
Lars W Andersen, Mathias J Holmberg, Maria Høybye...
https://pubmed.ncbi.nlm.nih.gov/37543161/Actively Recruiting
Led by Tiohundra AB · Updated on 2022-01-20
1276
Participants Needed
2
Research Sites
12 weeks
Total Duration
Researchers are conducting a randomized, placebo-controlled, double-blind clinical trial to evaluate treatments for patients who experience in-hospital cardiac arrest and require adrenaline according to current guidelines. The study aims to determine whether adding vasopressin and steroids to adrenaline improves survival rates compared to adrenaline alone. The trial is expected to run for 3 to 4 years and will enroll about 1400 patients. Patients who have a cardiac arrest in the hospital and meet criteria for adrenaline administration will be randomly assigned to receive either adrenaline combined with vasopressin and steroids or adrenaline with a placebo sodium chloride. The intervention group receives vasopressin during CPR cycles and methylprednisolone during the first cycle, followed by hydrocortisone infusion for up to seven days in the ICU for those with post-resuscitation shock. The control group receives sodium chloride as a placebo during CPR and in the ICU at similar schedules. Participants will be monitored closely with survival at 30 days as the primary outcome measure. The study includes informed consent procedures for hospitalized men over 18 and women over 50 years old, excluding certain groups based on capacity to consent, pregnancy potential, and prior enrollment. The trial uses quadruple masking and randomization to ensure unbiased results, with data collected throughout the treatment and follow-up periods.
CONDITIONS
VAsopressin and STeroids in Addition to Adrenaline in Cardiac Arrest - a Randomized Clinical Trial
S
Sune Forsberg, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Tiohundra AB
Lead Sponsor
Sahlgrenska University Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 7 days of active drug infusion after resuscitation, with tapering thereafter
Participants receive vasopressin, methylprednisolone, and hydrocortisone or placebo alongside adrenaline during cardiac arrest and subsequent ICU care.
Treatment is administered during resuscitation and daily infusions in the ICU for up to 7 days post-resuscitation
Duration - 30 days
Participants are monitored for survival and recovery outcomes up to 30 days after treatment.
Follow-up visits or assessments occur up to 30 days post-treatment
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Lars W Andersen, Mathias J Holmberg, Maria Høybye...
https://pubmed.ncbi.nlm.nih.gov/37543161/Tiohundra AB
Lead Sponsor
Sahlgrenska University Hospital
Collaborating Sponsor